Category Archives: General HIV+ population

BACKGROUND: The diagnostic value of interferon-gamma release assays (IGRAs) for active tuberculosis in low- and middle-income countries is unclear. METHODS: We searched multiple databases for studies published through May 2010...

OBJECTIVE: to assess the clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis c virus (HCV) in three specific patient subgroups affected by recent...

Treatment guidelines recommend dual nucleoside reverse transcriptase inhibitors (NRTI ) as a part of combination antiretroviral therapy. The objective of this study was to assess the relative efficacy and toxicity...

BACKGROUND: Immunocompromised patients are vulnerable to severe or complicated influenza infection. Vaccination is widely recommended for this group. This systematic review and meta-analysis assesses influenza vaccination for immunocompromised patients in...

OBJECTIVE: A ‘test and treat’ strategy to reduce HIV transmission hinges on linking and retaining HIV patients in care to achieve the full benefit of antiretroviral therapy. We integrated empirical...

No abstract.

OBJECTIVE: To present a review of barriers impeding people living with HIV/AIDS in developing countries from accessing treatment, and to make recommendations for further studies. METHODS: Electronic databases, websites of...

Two-thirds of the world’s HIV-infected people live in sub-Saharan Africa, and more than 1.5 million of them die annually. As access to antiretroviral treatment has expanded within the region; early...

OBJECTIVES: The aim of this study was to assess the effects of peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus (HIV). METHODS: Trials were identified...

Background: Rifamycins are an essential component of modern short-course regimens for treating tuberculosis. Rifabutin has favourable pharmacokinetic and pharmacodynamic properties and is less prone to drugdrug interactions than rifampicin. It...

Background: Preventing active tuberculosis (TB) from developing in people with latent tuberculosis infection (LTBI) is important for global TB control. Isoniazid (INH) for six to nine months has 60% to...

OBJECTIVES: Successful antiretroviral therapy (ART) is largely attributed to the type of third drug. Guidelines recommend regimens without systematic review of all factors that might affect treatment success, such as...